These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33809082)

  • 61. Inter- and intralaboratory comparison of JC polyomavirus antibody testing using two different virus-like particle-based assays.
    Kardas P; Sadeghi M; Weissbach FH; Chen T; Hedman L; Auvinen E; Hedman K; Hirsch HH
    Clin Vaccine Immunol; 2014 Nov; 21(11):1581-8. PubMed ID: 25253664
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
    Miranda Acuña JA; Weinstock-Guttman B
    Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
    [TBL] [Abstract][Full Text] [Related]  

  • 63. JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?
    Diotti RA; Nakanishi A; Clementi N; Mancini N; Criscuolo E; Solforosi L; Clementi M
    Clin Dev Immunol; 2013; 2013():967581. PubMed ID: 23878587
    [TBL] [Abstract][Full Text] [Related]  

  • 64. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
    Outteryck O; Zéphir H; Salleron J; Ongagna JC; Etxeberria A; Collongues N; Lacour A; Fleury MC; Blanc F; Giroux M; de Seze J; Vermersch P
    Mult Scler; 2014 Jun; 20(7):822-9. PubMed ID: 24072722
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
    De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
    J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Detection of human neurotropic JCPyV DNA sequence in pediatric anaplastic xanthoastrocytoma.
    Passerini S; Prezioso C; Prota A; Babini G; Bargiacchi L; Bartolini D; Moens U; Antonelli M; Pietropaolo V
    J Neurovirol; 2023 Apr; 29(2):232-236. PubMed ID: 37097595
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Natalizumab-associated progressive multifocal leukoencephalopathy in Germany.
    Blankenbach K; Schwab N; Hofner B; Adams O; Keller-Stanislawski B; Warnke C
    Neurology; 2019 May; 92(19):e2232-e2239. PubMed ID: 30952796
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Reactivation of JC virus and development of PML in patients with multiple sclerosis.
    Khalili K; White MK; Lublin F; Ferrante P; Berger JR
    Neurology; 2007 Mar; 68(13):985-90. PubMed ID: 17389301
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The link between VLA-4 and JC virus reactivation.
    Monaco MC; Major EO
    Expert Rev Clin Immunol; 2012 Jan; 8(1):63-72. PubMed ID: 22149341
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Establishment of COS-JC cells persistently producing archetype JC polyomavirus.
    Nukuzuma S; Nukuzuma C; Kameoka M; Sugiura S; Nakamichi K; Tasaki T; Hidaka K; Takegami T
    Microbiol Immunol; 2018 Aug; 62(8):524-530. PubMed ID: 29932215
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.
    Barroso B; Miquel M; Marasescu R; Demasles S; Krim E; Bonnan M
    Mult Scler Relat Disord; 2015 Jul; 4(4):380-2. PubMed ID: 26195060
    [TBL] [Abstract][Full Text] [Related]  

  • 74. JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis.
    Ciardi MR; Zingaropoli MA; Iannetta M; Prezioso C; Perri V; Pasculli P; Lichtner M; d'Ettorre G; Altieri M; Conte A; Pietropaolo V; Mastroianni CM; Vullo V
    Virol J; 2020 Feb; 17(1):23. PubMed ID: 32046748
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
    Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PML risk stratification using anti-JCV antibody index and L-selectin.
    Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
    Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Lack of specific T- and B-cell clonal expansions in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Bertoli D; Sottini A; Capra R; Scarpazza C; Bresciani R; Notarangelo LD; Imberti L
    Sci Rep; 2019 Nov; 9(1):16605. PubMed ID: 31719595
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr virus and -measles/-rubella/-varicella-zoster-virus antibodies.
    Auer M; Borena W; Holm-von Laer D; Deisenhammer F
    J Med Virol; 2017 Jan; 89(1):3-9. PubMed ID: 27253624
    [TBL] [Abstract][Full Text] [Related]  

  • 79. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.
    Rinaldi L; Rinaldi F; Perini P; Calabrese M; Seppi D; Grossi P; Mattisi I; Barzon L; Mengoli C; Sanzari M; Palú G; Gallo P
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1345-50. PubMed ID: 20547618
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients.
    Dalla Costa G; Martinelli V; Moiola L; Sangalli F; Colombo B; Finardi A; Cinque P; Kolb EM; Haghikia A; Gold R; Furlan R; Comi G
    Ann Neurol; 2019 Apr; 85(4):606-610. PubMed ID: 30761586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.